Imiquimod
11 NDCs across 6 manufacturers|8 Generic,3 Brand
Imiquimod is used to treat basal cell carcinoma, condylomata acuminata and actinic keratosis, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Feb 27, 1997, and the first generic was approved Feb 25, 2010. FDA's Orange Book lists 6 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $7 million on Imiquimod across 213,000 claims for 141,000 beneficiaries.
Imiquimod is available as 11 NDCs from 6 manufacturers (8 generic, 3 brand), with NADAC prices from $0.61 to $36.23 per EA — the most expensive product costs about 59× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
11
8G / 3B
Manufacturers
6
competing in market
Price Spread
$0.61 – $36.23
per EA, 6 of 11 NDCs
7d Activity
avg -0.7% WoW · of 11 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Bausch Health US LLC manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
6 manufacturers producing IMIQUIMOD
| Drug ↕ | Price | 7d Change ↕ |
|---|---|---|
ZYCLARA 3.75% CREAM PUMP | $158.1732 per GM | — |
ZYCLARA 2.5% CREAM PUMP | $158.0445 per GM | — |
IMIQUIMOD 3.75% CREAM PUMP | $113.1215 per GM | +5.68% |
IMIQUIMOD 3.75% CREAM PUMP | $113.1215 per GM | +5.68% |
IMIQUIMOD 3.75% CREAM | $36.2285 per EA | +0.03% |
ZYCLARA 3.75% CREAM | $36.0836 per EA | — |
IMIQUIMOD 3.75% CREAM PUMP | $24.3913 per GM | — |
IMIQUIMOD 5% CREAM PACKET | $12.1655 per EA | +0.17% |
IMIQUIMOD 5% CREAM PACKET | $0.6099 per EA | -5.37% |
IMIQUIMOD 5% CREAM PACKET | $0.6099 per EA | -5.37% |
IMIQUIMOD 5% CREAM PACKET | $0.6099 per EA | -5.37% |
Frequently Asked Questions
What is Imiquimod used to treat?
Imiquimod is used to treat basal cell carcinoma, condylomata acuminata and actinic keratosis, per the National Library of Medicine's MED-RT classification.
When did Imiquimod become available as a generic?
FDA approved the first generic Imiquimod (ANDA) on Feb 25, 2010. The Orange Book currently lists 6 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Imiquimod?
In 2024, Medicare Part D spent $7 million on Imiquimod across 213,000 claims for 141,000 beneficiaries.
How many Imiquimod products are on the market?
The Imiquimod drug market contains 11 NDCs from 6 manufacturers — 8 generic and 3 brand products.
What is the price range for Imiquimod?
NADAC reference prices for Imiquimod range from $0.6099 to $36.2285 per EA — the most expensive product costs about 59× the cheapest. 5 additional products are priced per different units (e.g. liquids per ML) and aren't directly comparable.
Is generic Imiquimod cheaper than brand?
The average generic NADAC for Imiquimod is $10.0447 per EA, versus $36.0836 for brand-labeled products — brand versions average about 3.6× the generic price.
Which manufacturers make Imiquimod?
6 manufacturers list Imiquimod in NADAC. Ranked by number of NDCs, the largest are Bausch Health US LLC (3), Sun Pharmaceutical Industries Inc. (3), Padagis Israel Pharmaceuticals Ltd (2), Teva Pharmaceuticals USA Inc. (1), Oceanside Pharmaceuticals (1).
How has the price of Imiquimod changed recently?
Over the past 7 days, 4 Imiquimod NDCs rose and 3 fell, with a market-wide average change of -0.7%.